How to Source Non-IMP Supplies for Clinical Trials
Tim Holmes, Manager, Clinical Oversight of Supplies, Biogen, offers considerations on how to obtain non-IMP...
Read More...
Focus:
-
![]()
GDPR: The Implications for Clinical Development
Eight months in, Nigel Hughes, Scientific Director JCI-PDR, Janssen, examines the ramifications of GDPR on...
Read More...
-
![]()
Industry Viewpoints: Patient Recruitment and Expanded Access
In the latest Industry Viewpoint, Howard Fingert speaks to CTA’s Elizabeth Williams about the challenges...
Read More...
-
![]()
Managing Blinding Requirements in IRT: An Overview
Francesco Spoto, Clinical Project Manager, explores the opportunities of using IRT solutions to manage blinded...
Read More...
-
![]()
Industry Viewpoints: Clinical Trials in Asia – Key Considerations
Mainfong Ang, Amgen, sits down with CTA’s Jisong Seo about the difficulties of clinical operations...
Read More...
-
![]()
Observations from GCP Sponsor Inspections
Kevin Anderson, Director, Global Clinical Operations, Alexion Pharmaceuticals, offers a perspective on what he has...
Read More...
-
![]()
Is the GAIN Act Stimulating Antibiotic R&D?
Christopher J. Pace, PhD, Director of Infectious Diseases, GlobalData, assesses the impact of the GAIN...
Read More...
-
![]()
Strategic Comparator Sourcing – A Matter of High Priority
Ian Hoban, Pilatus Comparator Solutions, poses some key questions that should be front of mind...
Read More...
-
![]()
New Data Suggest HCV Remains a Problem in the US
Topias Lemetyinen, Senior Epidemiologist, GlobalData, explains why HCV continues to be an enduring issue in...
Read More...
-
![]()
How to Enable Greater Budget Forecasting
Ken Olovich, R.Ph., MBA, Sourcing and Financial Director of Chorus, Eli Lilly, explains a model...
Read More...
